10/20/2025 04:00
Worldwide First: Biedermann Motech Further Expands its MOSS!MODULARITY Platform and Announces Introduction of Multiple New Products

Biedermann Motech, the prominent innovator in next generation spinal and extremity implant systems and procedural solutions, today announced the market introduction of several additions to its MOSS!MODULARITY™ platform. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251019799867/en/MOSS!MODULARITY Injection Screw MOSS!MODULARITY encompasses a broad range of products and technologies for spinal surgery based around the concept of pro...

10/20/2025 06:00
Lazard Appoints Edouard Panié as Managing Director and Co-Head of European Financial Sponsors Coverage

Lazard, Inc. (NYSE: LAZ) today announced the appointment of Edouard Panié as Managing Director and Co-Head of the European Financial Sponsors Coverage. He will report to Klaus H. Hessberger, Global Co-Head and Head of Europe for Lazard’s Financial Sponsors Group, to further strengthen the firm’s presence and partnerships with financial sponsors across the region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251019307537/en/Edouard...

10/20/2025 06:00
Iksuda Presents Encouraging IKS014 Phase 1 Data at ESMO

Iksuda Therapeutics (Iksuda), the developer of class leading, antibody drug conjugates (ADCs), today announces the presentation of new data from its Phase 1 study of IKS014, a human epidermal growth factor receptor 2 (HER2)-directed ADC, in patients with advanced HER2+ solid tumours. The data was presented at the European Society for Medical Oncology (ESMO) Congress in Berlin, Germany. The Phase 1 study (NCT05872295) is a non-randomised, open-label, multicentre trial evaluating IKS014 in pati...